However, treatment regimens including PD-1/PD-L1 antibodies as monotherapy or in combination with standard therapies failed to care for patients suffering from pancreatic [54] or colon cancer [55], leading to recurrence [56]. This evidence concerns the gene PDCD1 and colonic neoplasm.